Global net sales of Idorsia’s drug candidate QUVIVIQ increased by >130% year-on-year to CHF 91 million in nine months during 2025, setting Idorsia on track to reach profitability by 2027. Oculis, which is dedicated to addressing eye-related conditions, has raised an oversubscribed $110 investment to accelerate the development of its novel neuroprotective clinical candidate, Privosegtor..

Idorsia的候选药物QUVIVIQ的全球净销售额在2025年的九个月内同比增长超过130%，达到9100万瑞士法郎，使Idorsia有望在2027年实现盈利。专注于治疗眼部相关疾病的Oculis已经超额完成了一轮1.1亿美元的融资，以加速其新型神经保护临床候选药物Privosegtor的开发。

Idorsia

Idorsia

is a Basel-based biotech company focused on the discovery, development, and commercialization of transformative medicines – either with in-house capabilities or together with partners. Its lead candidate QUVIVIQ™ (daridorexant) is a dual orexin receptor antagonist indicated for the treatment of adult patients with .

是一家总部位于巴塞尔的生物技术公司，专注于发现、开发和商业化变革性药物——要么依靠内部能力，要么与合作伙伴共同进行。其主要候选药物QUVIVIQ™（达利多雷克斯）是一种双重食欲素受体拮抗剂，用于治疗成年患者。

insomnia

失眠症

– characterized by difficulty falling asleep and/or maintaining sleep. QUVIVIQ has been approved without psychotropic drug control labeling, underscoring its differentiated clinical profile.

– 特点是难以入睡和/或保持睡眠。QUVIVIQ 已获批且未带有精神药物管制标签，突显了其差异化的临床特性。

Currently available in 13 countries – including the US, Cananda Europe (Germany, Italy, Switzerland, Spain, the UK, Austria, France, Sweden, Finland), Japan and in China through a partnership with Simcere Pharmaceuticals – QUVIVIQ has demonstrated strong sales performance in the last nine months. Global net sales for this therapy increased by >130% year-on-year to CHF 91 million, pushing the company towards profitability by the end of 2027..

目前，QUVIVIQ已在13个国家上市，包括美国、加拿大、欧洲（德国、意大利、瑞士、西班牙、英国、奥地利、法国、瑞典、芬兰）、日本，并通过与先声药业的合作在中国上市。在过去的九个月中，QUVIVIQ展现了强劲的销售表现。该疗法的全球净销售额同比增长超过130%，达到9100万瑞士法郎，推动公司朝着在2027年底前实现盈利的目标迈进。

In addition to QUVIVIQ, Idorsia's dual ERA drug, TRYVIO (aprocitentan), which addresses systemic hypertension, is gaining recognition as the only new medicine included in the US ACC/AHA Hypertension Management guidelines. Real-world evidence supports its benefits, particularly for patients with uncontrolled hypertension and chronic kidney disease..

除了QUVIVIQ之外，Idorsia的双重ERA药物TRYVIO（aprocitentan）针对系统性高血压，作为唯一被纳入美国ACC/AHA高血压管理指南的新药而获得认可。真实世界证据支持其益处，特别是对未控制的高血压和慢性肾病患者。

Overall, Idorsia’s operating expenses decreased significantly due to cost controls and operational restructuring. Following a CHF 65.6 million financing round, the company's cash runway was extended beyond profitability through 2028. Idorsia reported net revenue of CHF 173 million in the first nine months of 2025, compared to CHF 53 million in the same period the previous year..

总体而言，由于成本控制和业务重组，Idorsia的运营费用显著减少。在完成一轮6560万瑞士法郎的融资后，公司现金流足以支撑其运营至2028年实现盈利。Idorsia报告称，2025年前九个月的净收入为1.73亿瑞士法郎，而上一年同期为5300万瑞士法郎。

Oculis closes oversubscribed round

Oculis完成超额认购轮融资

Oculis

眼睛

has raised $110 million through an oversubscribed offering of 5,432,098 at a price of $20.25 per share – before deducting underwriting discounts and commissions and offering expenses. The financing includes an underwritten offering of 4,691,358 shares and a registered direct offering of 740,740 shares, with an additional 30-day option for underwriters to purchase up to 703,703 more shares.

通过超额认购的 5,432,098 股发行，每股价格为 20.25 美元，已筹集了 1.1 亿美元——尚未扣除承销折扣、佣金和发行费用。此次融资包括 4,691,358 股的包销发行和 740,740 股的注册直接发行，承销商还拥有 30 天的选择权，可以额外购买最多 703,703 股。

Of the total shares offered, 2,635,801 are newly issued from the company’s existing capital band (Kapitalband), and 3,500,000 are treasury shares previously held by the company. The issuance of the new shares will increase the total number of authorized registered shares to 57,169,475 as per the company’s Articles of Association..

在所提供的总股数中，2,635,801股是公司现有资本带（Kapitalband）新发行的股票，3,500,000股是公司之前持有的库存股。新股的发行将使根据公司章程授权的注册股总数增加至57,169,475股。

The net proceeds will be used to advance and accelerate the development of Privosegtor, a neuroprotective candidate for the treatment of optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes..

净收益将用于推动和加速神经保护候选药物Privosegtor的开发，该药物用于治疗视神经病变，如急性视神经炎（AON）和非动脉前缺血性视神经病变（NAION），同时也将用于营运资金和一般公司用途。

Oculis clinical pipeline also includes OCS-01, an eye-drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED)..

Oculis的临床管线还包括OCS-01，这是一种处于关键注册研究阶段的眼药水，旨在成为首个用于糖尿病性黄斑水肿（DME）的非侵入性局部治疗药物；以及Licaminlimab，一种新型的局部抗TNFα药物，目前处于二期临床阶段，该药物基于基因型方法开发，致力于推动干眼病（DED）的个性化医疗。

(RAN)

(无线接入网)

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送